Dr. Umar

This study examined gut microbiota differences in women with premenstrual symptoms, identifying decreases in key butyrate-producing and GABA-modulating bacteria linked to symptom severity, suggesting mechanistic microbiome pathways relevant to PMDs.

This study integrates fungal and bacterial sequencing to define pathogen-specific microbiome signatures in vulvovaginal candidiasis, revealing distinct CSTs shaped by C. albicans or C. glabrata and their associated bacterial communities.

The study identifies a postpartum depressive disorder microbiome signature marked by reduced butyrate-producing bacteria and increased inflammatory taxa, correlated with depression severity and sex hormone levels.

This study compared fertile and infertile women’s gut microbiota and assessed PHGG’s effects on dysbiosis and pregnancy during ART, highlighting key microbial predictors of conception.

This study examined vaginal microbiome signatures in women with secondary infertility, identifying Lactobacillus depletion and anaerobic enrichment, with limited microbiome response to IVF-related hormonal induction.

This study links vaginal microbiota composition—especially Lactobacillus iners dominance and Pseudomonadaceae enrichment—to IVF outcomes in women with PCOS or tubal infertility, highlighting microbial markers that may predict implantation success.

This study identifies distinct microbiome signatures in breast tissue and urine of women with breast cancer, including decreased Methylobacterium and increased gram-positive taxa, revealing potential microbial biomarkers for disease detection.

This study analyzed menopausal-specific gut microbiota patterns in Taiwanese women and found distinct microbial signatures in premenopausal breast cancer, including reduced diversity and key shifts in protective and procarcinogenic taxa with strong diagnostic potential.

This study links estrogen levels to oral microbiome composition, inflammation, and viral load in COVID-19, identifying microbial signatures across hormonal groups that highlight estrogen’s protective role in maintaining oral microbial balance.

This study links altered vaginal microbiota—especially shifts in Lactobacillus species—to hormonal disruption in primary ovarian failure, revealing microbial signatures that correlate with reproductive hormone levels and resemble menopausal microbiome patterns.

This study examined how the premature ovarian insufficiency vaginal microbiome differs from healthy controls, identifying key microbial shifts linked to hormone disruption and ovarian dysfunction.

This study examined the vaginal microbiome in premature ovarian insufficiency, identifying reduced Lactobacillus, increased dysbiosis-associated taxa, and strong hormone–microbe correlations that suggest a microbiome–ovary interaction.

This study links menopausal syndrome with gut microbiome dysbiosis, identifying species correlated with estradiol and enriched metabolic pathways that may influence symptom severity and cardiometabolic risk.

GWUAP modulates gut microbiota and metabolites in a dysmenorrhea rat model, restoring Lactobacillus, reducing Romboutsia, correcting hormone-related metabolic pathways, and improving inflammatory and pain outcomes.

This study compared gut microbiome in early-stage and late-stage endometriosis, revealing distinct microbial signatures, steroid metabolism suppression in severe disease, and a unique dysmenorrhea-associated subtype.

This study mapped vaginal microbiome and metabolome shifts across common infections, showing Lactobacillus loss, anaerobe expansion and metabolite disruptions that define distinct microbial fingerprints.

This study evaluated how Cesarean versus vaginal birth shapes adult vaginal microbiota, identifying links between C-section birth, reduced Lactobacillus dominance, and increased Prevotella bivia abundance.

This study analyzes how BV, HPV, and CIN interact to alter vaginal microbiome structure, highlighting L. iners enrichment and increased diversity as signatures of dysbiosis linked to CIN risk.

Metaproteomic profiling revealed Candida-rich communities in BV-negative women, while Malassezia and Conidiobolus characterized BV-positive states. Functional shifts and strong fungal–bacterial associations highlight intertwined ecological dynamics.

This study links CAD to depletion of SCFA-producing microbes and disrupted interferon-related gene expression, forming an integrated microbiome–transcriptome signature with diagnostic potential.

Ovarian cancer is one of the most lethal cancers affecting women worldwide. Known for its “silent” progression, this disease often goes undetected until it reaches advanced stages, making early diagnosis crucial for improving survival outcomes. With a variety of subtypes, ovarian cancer presents unique challenges in both treatment and prevention. Recent advancements in research are shining a light on the importance of the microbiome, particularly how microbial imbalances in the gut and vaginal microbiota can influence cancer progression. Repurposed drugs such as metformin and innovative interventions like probiotics, microbiota transplantation, and intratumoral microbiota therapies offer promising new avenues for improving ovarian cancer treatment.

This study identifies distinct microbial signatures in ovarian carcinoma, including increased Proteobacteria and reduced Firmicutes, with Acinetobacter lwoffii and Lactococcus piscium emerging as key taxa linked to tumor biology and diagnostic potential.

This study identifies distinct ovarian microbiome differences between cancerous and noncancerous tissues, showing altered taxa and enriched pathogenic and oxidative stress–tolerant functions in ovarian cancer.

This study identifies distinct microbial signatures that differentiate ovarian cancer from benign conditions and reveal early-stage enrichment of pathogenic taxa with depletion in advanced disease, highlighting promising diagnostic and prognostic microbiome biomarkers for ovarian cancer.